DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Average Recommendation of “Hold” by Brokerages

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been assigned an average recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company.

DSRLF has been the topic of a number of recent analyst reports. Piper Sandler initiated coverage on shares of DiaSorin in a research report on Thursday. They set a “neutral” rating on the stock. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. Finally, Zacks Research upgraded shares of DiaSorin to a “hold” rating in a report on Tuesday, May 12th.

DiaSorin Stock Performance

DSRLF stock opened at $84.10 on Monday. DiaSorin has a 52 week low of $66.50 and a 52 week high of $112.30. The firm’s 50-day moving average is $71.24 and its two-hundred day moving average is $75.22.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.